SCHEMBL23959602

SCHEMBL23959602

C[C@H]1CN(C(=O)c2nn(CC(=O)N3CCC(Oc4ccc(F)c(F)c4)CC3)c3c2CCC3)CCO1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.40
CNR1 P21554 2/20 0.40
GRIN2B Q13224 3/20 0.39
GRIN1 Q05586 2/20 0.35
HRH1 P35367 1/20 0.35
CCR3 P51677 1/20 0.35
PIK3CD O00329 1/20 0.35
PIK3R2 O00459 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CB P42338 1/20 0.35
PIK3CG P48736 1/20 0.35
PIK3R5 Q8WYR1 1/20 0.35
PIK3R3 Q92569 1/20 0.35
ALOX15 P16050 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
HCRTR1 O43613 1/20 0.34
HCRTR2 O43614 1/20 0.34
HRH3 Q9Y5N1 2/20 0.34
IDO1 P14902 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21752511 0.93 KMT2A (0.47) KMT2ACNR1GRIN2BGRIN1HRH1
SCHEMBL32685318 0.93 KMT2A (0.47) KMT2ACNR1GRIN2BGRIN1HRH1
SCHEMBL23959578 0.90 MLNR (0.43) KMT2ACNR1GRIN2BPIK3CDPIK3R2
SCHEMBL23959626 0.90 KMT2A (0.43) KMT2ACNR1PIK3CDPIK3R2PIK3CA
SCHEMBL23959556 0.89 KMT2A (0.44) KMT2AGRIN2BPIK3CDPIK3R2PIK3CA
SCHEMBL23959580 0.89 CNR1 (0.42) KMT2ACNR1PIK3CDPIK3R2PIK3CA
SCHEMBL23959594 0.88 KMT2A (0.43) KMT2ACNR1PIK3CDPIK3R2PIK3CA
SCHEMBL23959539 0.88 KDM4E (0.41) KMT2AGRIN2BPIK3CDPIK3R2PIK3CA
SCHEMBL23959560 0.88 LIPE (0.43) KMT2ACNR1ALOX15POLBADRB2
SCHEMBL21752645 0.88 KMT2A (0.47) KMT2ACNR1GRIN2BALOX15HCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210330676-A1 NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210330676-A1 NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS IDO1, IDO2, KYNU KMT2A 1461/4885CNR1 1075/4885GRIN2B 1302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.